Expression of Her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches

Martin R. Müller, Frank Grünebach, Katrin Kayser, Wichard Vogel, Alessio Nencioni, Wolfram Brugger, Lothar Kanz, Peter Brossart

Research output: Contribution to journalArticle

Abstract

Her-2/neu is a tumor-associated antigen that is expressed on several adenocarcinomas and correlates with poor prognosis. In a previous study (H. J. Bühring et al., Blood, 86: 1916-1923, 1995), it has been demonstrated that Her-2/neu expression can be detected on blast cells from patients with hematological malignancies including acute lymphoblastic leukemia (ALL). Here, we show that Her-2/ neu-specific CTLs induced in vitro using peptide-pulsed dendritic cells efficiently lyse primary ALL blasts constitutively expressing both Her-2/neu and human leukocyte antigen A2 in an antigen-specific and MHC-restricted manner. Furthermore, we analyzed the feasibility of this approach in an autologous setting and induced Her-2/neu-specific CTLs using dendritic cells generated from peripheral blood mononuclear cells from an ALL patient that were pulsed with peptides or transfected with in vitro-transcribed Her-2/neu mRNA. Our data demonstrate that Her-2/neu could be used as a potential target for the application of Her-2/neu-directed treatment strategies in ALL including vaccination approaches.

Original languageEnglish
Pages (from-to)3448-3453
Number of pages6
JournalClinical Cancer Research
Volume9
Issue number9
Publication statusPublished - Sep 1 2003

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Expression of Her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches'. Together they form a unique fingerprint.

  • Cite this

    Müller, M. R., Grünebach, F., Kayser, K., Vogel, W., Nencioni, A., Brugger, W., Kanz, L., & Brossart, P. (2003). Expression of Her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches. Clinical Cancer Research, 9(9), 3448-3453.